cytogenetically normal-acute myeloid leukemia
Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients.
... with normal karyotype represent the single largest cytogenetic group of acute myeloid leukemia (AML), with highly heterogeneous clinical and molecular ...in cytogenetically ...
10
Aberrant Chloride Intracellular Channel 4 Expression Is Associated With Adverse Outcome in Cytogenetically Normal Acute Myeloid Leukemia
... INTRODUCTION Acute myeloid leukemia (AML) is a genetically and clinically heterogeneous hematopoietic ...as cytogenetically normal AML (CN-AML) patients, are still not well understood ( ...
14
Understanding the transcriptional control of EIF4E and its dysregulation in acute myeloid leukemia: role of NF-κB
... or normal primary hematopoietic cells and thus represents an underlying factor in determining the differential expression of EIF4E in ...the cytogenetically favorable ...
154
Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)
... As in P17 CXCR4-low PDX model, receptor occupancy by PF-06747143 on leukemic cells was observed 24 hours after each treatment (Supplemental Figure 3C ). During treatment, both the percentage (Fig. 7A ) and the total ...
14
Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the LEA program
... Impairment in several domains of QoL has been described in childhood cancer survivors, but to the best of our knowledge, our study is the first to focus on the impact of late cardiac dysfunction. It is worthy of note ...
5
ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.
... and leukemia-free survival ...–4 acute GVHD, systemic therapy-requiring chronic GVHD, relapse, or death in the first post- HCT year, and severity of acute and chronic ...of leukemia in bone ...
8
Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3‐ITD‐driven acute myeloid leukemia
... Introduction Acute myeloid leukaemia (AML) is a clonal disorder that affects hematopoietic stem cells or myeloid ...the normal growth and differentiation of hematopoietic cells via the ...
24
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia
... We then used a ChIP-qPCR approach to dissect the sequential events involved in EVI1- induced CKMT1 upregulation and the possible role of RUNX1 as an intermediate in this process (Figure 3H–3L). Multiple red peaks ...
34
Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia
... In Acute Myeloid Leukemia (AML), a complete response to chemotherapy is usually obtained after conventional chemotherapy but overall patient survival is poor due to highly frequent ...chronic ...
19
Analysis of the proteasome-autophagy crosstalk under proteotoxic stress conditions in acute myeloid leukemia
... of normal and cancer cells (Lum et ...in normal cells and in tumor cells seems to contradict the observation that loss-of-function mutations in the autophagy pathway are associated with tumor progression ...
222
H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations
... occurred at a variant allele frequency (VAF) of less than 50%, suggesting a minor hemizygous mutant sub-clone (Figure 9a). Gene expression profiles revealed that the mutated H3.1 gene contributed to 27.8% of total ...
89
View of Specific pulmonary involvement in acute myeloid leukemia: from diagnosis to treatment
... Dans une étude rétrospective portant sur 20 patients atteints de LAM5 et admis en réanimation pour une IRA secondaire à une leucostase pulmonaire ou une infiltration pulmonaire leu- cémi[r] ...
8
en fr Targeting NPM1c in Acute Myeloid leukemia NPM1C, une cible dans le traitement des leucémies aigues myéloides
... From www.bloodjournal.org by guest on May 9, 2019. For personal use only. BLOOD, 28 MAY 2015 x VOLUME 125, NUMBER 22 RA/ARSENIC DEGRADE MUTANT NPM1 3453 observe complete remissions, the leukemia clearly regressed ...
241
Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients
... Acute myeloid leukemia (AML) intensive chemotherapy combined with broad-spectrum antibiotics, leads to gut microbiota dysbiosis promoting pathological conditions and an increased incidence of ...
12
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
... three dose intensity levels by using the threshold myeloa- blative dose as the intermediate dose level and assigning all doses below or above to the low or high dose level, respectively. For each of these components, we ...
12
Isolated granulocytic sarcoma of the pancreas: A tricky diagnostic for primary pancreatic extramedullary acute myeloid leukemia
... of myeloid lineage with positive immunostaining for CD43 myeloid-associated antigen (Figure 1A), whereas immunostainings for other myeloid markers (CD31, CD34, CD38, CD45, CD99, CD117), B-cell ...
6
Practical management of Chronic Myeloid Leukemia in Belgium
... chronic myeloid leukaemia, with the majority of them showing a normal life ...chronic myeloid leukaemia are presented adapted to the Belgian situation in ...chronic myeloid leukaemia risk ...
17
A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia
... Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R γc-deficient ...of acute mye- logenous leukemia progenitors that initiate malignant ...
8
Acute lymphoblastic leukemia in children
... Le nombre (n = 13 soit 16,5 %) d’échecs thé- rapeutiques (rechutes et patients réfractaires : plus de 25 % de blastes après l’induction) que nous avons observé est bas mais le taux de “r[r] ...
7
Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON leukemia group trials
... Secondary acute myeloid leukemia (sAML) describes patients (pts) with a history of malignant or non-malignant disease or AML secondary to environmental, occupational or therapeutic ...
3